June 6, 2022
Uppsala, Sweden – Strike Pharma, the company using its proprietary Adaptable Drug Affinity Conjugate (ADAC™) technology platform to develop individualized immunotherapeutic treatments, today announced the appointment of Lindvi Gudmunsdotter Ph.D. as Director, Non-Clinical Development. As a member of the Strike Pharma team, Lindvi will have overall responsibility for taking the company’s therapeutic vaccine candidates through pre-clinical stages prior to clinical trials.
Tina Furebring, Commercial Operations Officer at Strike Pharma commented, “We are extremely pleased to welcome Lindvi to Strike Pharma. As former Director Translational Medicine at the Swedish biopharmaceutical company, Affibody AB, she brings a wealth of knowledge and commercial experience in the development of biotherapeutics within young, dynamic organizations.”
Beginning with a Ph.D. in Medical Science from the world-renowned Karolinska Institute in Stockholm, Lindvi has worked in highly relevant vaccine research, published many peer-reviewed publications and is a co-inventor of several patents.
Mårten Winge, CEO of Strike Pharma added, “Following our recent successful financing round, we are now in a position to expand. Engaging such experienced, senior individuals enables us to accelerate our efforts in bringing our first candidate to clinical trials and to further develop the ADAC technology platform.”
Today, Strike Pharma is focused on the development of novel, clinically-relevant candidates for use as immunotherapeutic vaccines in the treatment of solid tumors. By using ADAC technology, truly individualized treatments can be generated based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to increase therapeutic efficacy and reduce dosage levels, thereby minimizing the risk of side effects.
About Strike Pharma (www.strikepharma.com)
Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.
Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as immunotherapeutic vaccines in the treatment of solid tumors. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.
Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.
Mårten Winge CEO
+46 (0) 70 657 59 27